Skip to main content
. 2024 Mar 8;24:99. doi: 10.1186/s12935-024-03244-1

Table 1.

Clinical characteristics of the BC patients based on TCGA

Characteristic Low expression of NDUFAF6 High expression of NDUFAF6 P value
n 541 542
T stage, n (%) 0.944
T1 135 (12.5%) 142 (13.1%)
T2 314 (29.1%) 315 (29.2%)
T3 72 (6.7%) 67 (6.2%)
T4 18 (1.7%) 17 (1.6%)
N stage, n (%) 0.004
N0 271 (25.5%) 243 (22.8%)
N1 186 (17.5%) 172 (16.2%)
N2 40 (3.8%) 76 (7.1%)
N3 39 (3.7%) 37 (3.5%)
M stage, n (%) 0.130
M0 448 (48.6%) 454 (49.2%)
M1 6 (0.7%) 14 (1.5%)
Pathologic stage, n (%) 0.058
Stage I 90 (8.5%) 91 (8.6%)
Stage II 325 (30.7%) 294 (27.7%)
Stage III 109 (10.3%) 133 (12.5%)
Stage IV 5 (0.5%) 13 (1.2%)
Race, n (%) 0.043
Asian 22 (2.2%) 38 (3.8%)
Black or African American 100 (10.1%) 81 (8.1%)
White 387 (38.9%) 366 (36.8%)
Age, n (%) 0.104
 <  = 60 314 (29%) 287 (26.5%)
 > 60 227 (21%) 255 (23.5%)
Histological type, n (%) 0.001
Infiltrating ductal carcinoma 359 (36.7%) 413 (42.3%)
Infiltrating lobular carcinoma 122 (12.5%) 83 (8.5%)
PR status, n (%)  < 0.001
Negative 205 (19.8%) 137 (13.2%)
Indeterminate 3 (0.3%) 1 (0.1%)
Positive 309 (29.9%) 379 (36.7%)
ER status, n (%)  < 0.001
Negative 162 (15.7%) 78 (7.5%)
Indeterminate 0 (0%) 2 (0.2%)
Positive 356 (34.4%) 437 (42.2%)
HER2 status, n (%) 0.116
Negative 283 (38.9%) 275 (37.8%)
Indeterminate 3 (0.4%) 9 (1.2%)
Positive 71 (9.8%) 86 (11.8%)
PAM50, n (%)  < 0.001
Normal 34 (3.1%) 6 (0.6%)
LumA 294 (27.1%) 268 (24.7%)
LumB 40 (3.7%) 164 (15.1%)
Her2 46 (4.2%) 36 (3.3%)
Basal 127 (11.7%) 68 (6.3%)
Menopause status, n (%) 0.145
Pre 122 (12.6%) 107 (11%)
Peri 23 (2.4%) 17 (1.7%)
Post 331 (34.1%) 372 (38.3%)
Anatomic neoplasm subdivisions, n (%) 0.288
Left 272 (25.1%) 291 (26.9%)
Right 269 (24.8%) 251 (23.2%)
radiation_therapy, n (%) 1.000
No 219 (22.2%) 215 (21.8%)
Yes 280 (28.4%) 273 (27.7%)
Age, median (IQR) 56 (48, 66) 59 (49, 68) 0.048